利福平
鲍曼不动杆菌
利福霉素
抗生素
微生物学
利福平
头孢菌素
碳青霉烯
医学
病菌
分枝杆菌
生物
细菌
肺结核
克拉霉素
病理
铜绿假单胞菌
遗传学
作者
Vincent Trebosc,Christian Kemmer,Sergio Lociuro,Marc Gitzinger,Glenn E. Dale
标识
DOI:10.1016/j.drudis.2021.07.001
摘要
Rifamycin antibiotics were discovered during the 1950s, and their main representative, rifampicin, remains a cornerstone treatment for TB. The clinical use of rifamycin is restricted to mycobacteria and Gram-positive infections because of its poor ability to penetrate the Gram-negative outer membrane. Rifabutin, a rifamycin antibiotic approved for the prevention of Mycobacterium avium complex disease, makes an exception to this rule by hijacking the iron uptake system of Acinetobacter baumannii, resulting in potent activity against this important Gram-negative pathogen. Here, we describe recent findings on the specific activity of rifabutin and provide evidence of the need for the development of an intravenous formulation of rifabutin (BV100) for the treatment of difficult-to-treat carbapenem-resistant A. baumannii infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI